


Please type a plus sign (+) inside this box →



Substitute for form 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

## **Complete if Known**

Application Number	10/644,530
Filing Date	August 20, 2003
First Named Inventor	ROBERTS, Alan
Group Art Unit	1614
Examiner Name	SPIVACK
Attorney Docket Number	220551

Sheet 1 of 2

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			
PS	AA	6,407,128		Scaife et al.	Jun. 18, 2002	
PS	AB	6,455,557		Pellegrini et al.	Sep. 24, 2002	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
PS	AC	WO	01/08681	A1	First Horizon Pharmaceutical Corp.	Feb. 8, 2001		

## **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
PS	AD	Ali-Melkkila et al, "Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings," <i>Acta Anaesthesiol. Scand.</i> , 33: 513-517 (1989).		
PS	AE	Ali-Melkkila et al., "Pharmacokinetics and related pharmacodynamics of anticholinergic drugs," <i>Acta Anaesthesiol. Scand.</i> , 37: 633-642 (1993).		
PS	AF	Chen, "Troglitazone: An antidiabetic agent," <i>Am J. of Health-Syst. Pharm.</i> , 55: 905-925 (1998).		
PS	AG	Evans, "Influence of Dietary Components on the Gastrointestinal Metabolism and Transport of Drugs," <i>Therapeutic Drug Monitoring</i> , 22: 131-136 (2000).		
PS	AH	Greene et al., "Clinical Pharmacokinetics of Nefazodone," <i>Clin. Pharmacokinet.</i> , 33(4): 260-275 (1997).		
PS	AI	Gillen et al., "Problems related to acid rebound and tachyphylaxis," <i>Best Pract. &amp; Res. Clin. Gastroenterology</i> , 15(3): 487-495 (2001).		
PS	AJ	Kirk, "Significant Drug-Nutrient Interactions," <i>Amer. Fam. Phys.</i> , 51(5): 1175-1182 (1995).		
PS	AK	Loi et al., "Clinical Pharmacokinetics of Troglitazone," <i>Clin. Pharmacokinet.</i> , 37(2):91-104 (1999).		
PS	AL	Martinez et al., "A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals," <i>J. Clin. Pharmacol.</i> , 42: 620-643 (2002).		
PS	AM	Pelkonen et al., "In vitro prediction of gastrointestinal absorption and bioavailability: and experts' meeting report," <i>Eur. J. Clin. Pharmacol.</i> , 57: 621-629 (2001).		
PS	AN	Rautakorpi et al., "Pharmacokinetics and Oral Bioavailability of Glycopyrrolate in Children," <i>Pharmacology &amp; Toxicology</i> , 83: 132-134 (1998).		

Examiner Signature

*Phyllis Spivack*

Date Considered

11/13/05

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/644,530
				Filing Date	August 20, 2003
				First Named Inventor	ROBERTS, Alan
				Group Art Unit	1614
				Examiner Name	SPINACK
Sheet	2	of	2	Attorney Docket Number	220551

*(Use as many sheets as necessary)*

**Complete if Known**[illegible]

Examiner Signature	<i>[Signature]</i>	Date Considered	11/13/05
--------------------	--------------------	-----------------	----------

**Date Considered**

11/13/05

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).  
+ An English-language equivalent patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).